Neurolixis Announces Scientific Publication Demonstrating Rapid and Long-Lasting Antidepressant Activity of NLX-101 in a Robust Rodent Model
By: Neurolixis, Inc.
DANA POINT, Calif. - July 22, 2019 - PRLog -- Neurolixis, Inc. announced the publication of scientific data demonstrating rapid and long-lasting antidepressant activity of the Company's 'biased agonist' drug candidate, NLX-101 in a robust rodent model of depression. The study, published in the Journal of Psychopharmacology, showed that NLX-101 produced very rapid (i.e. within 1 day) and complete reversal of depressive-like behavior in rats subjected to chronic mild stress. Furthermore, the antidepressant-
The experiments were conducted in the laboratory of Prof. Mariusz Papp (Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland), a leading researcher in the field of antidepressant drugs. Prof. Papp commented: "The chronic mild stress model is highly validated and predictive of human antidepressant efficacy. Our laboratory has tested many antidepressant drugs, including reuptake inhibitors and ketamine, using the same conditions as those we used for NLX-101. However, none of the other drugs exhibited such rapid effects as NLX-101."
Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer of Neurolixis, commented: "We are excited about the remarkable activity of NLX-101 in this highly regarded model of depression. There is a great need for antidepressant drugs that are efficacious and well-tolerated. These striking results support our efforts to develop novel, rapid-acting, antidepressants based on the NLX-101 scaffold. If the rodent data translate to the clinic, these biased agonist compounds could significantly alleviate depression symptoms and other mood deficits, thus improving many patients' quality of life."
Details of the scientific publication
Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-
Depoortère R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney MA, Newman-Tancredi A. J Psychopharmacol. 2019. doi: 10.1177/0269881119860666. PMID: 31290370
About Novel 5-HT1A Receptor Biased Agonists
In collaboration with a team led by Dr. Marcin Kołaczkowski (Jagiellonian University, Krakow, Poland), Neurolixis is developing a series of potent and highly active 5-HT1A receptor biased agonists that are analogs of NLX-101 and exhibit promising in vitro selectivity, potent in vivo antidepressant-
About Major Depression
Major depression is a leading cause of disability with over 16 million patients in the USA. Most existing antidepressants act by inhibition of neurotransmitter reuptake but require many weeks of treatment before they are effective and only about half of patients respond satisfactorily. The anesthetic drug, ketamine, exhibits rapid-acting antidepressant (RAAD) activity in treatment-resistant patients but it elicits marked side-effects which limit its use. Recent findings indicate that ketamine indirectly activates 5-HT1A receptors in cortical brain regions, suggesting that their direct activation may elicit promising RAAD activity with improved safety and tolerability.
About Neurolixis, Inc.
Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the central nervous system. Its biased agonist drug discovery program targets major depression, NLX-101 is Phase 1-ready as a treatment for Rett syndrome (an orphan indication), and NLX-112 is Phase 2-ready as a treatment for L-DOPA-induced dyskinesia in Parkinsonian patients. Further information is available at http://www.neurolixis.com.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Mark Varney, CEO